NJH-2-030(Cat No.:I043916)is a selective small molecule inhibitor that targets specific proteins involved in cancer cell signaling, particularly those associated with cell survival and proliferation. It is primarily investigated for its potential therapeutic effects in cancer treatment, aiming to disrupt key molecular pathways that drive tumor growth and metastasis. NJH-2-030 has shown promise in preclinical studies for its ability to inhibit cancer cell progression, making it a valuable candidate in the development of targeted therapies. Its specificity and potency suggest potential applications in various cancer types and related diseases.